[go: up one dir, main page]

ATE66469T1 - Metall-radionuklid markiertes protein fuer diagnose und therapie. - Google Patents

Metall-radionuklid markiertes protein fuer diagnose und therapie.

Info

Publication number
ATE66469T1
ATE66469T1 AT86100360T AT86100360T ATE66469T1 AT E66469 T1 ATE66469 T1 AT E66469T1 AT 86100360 T AT86100360 T AT 86100360T AT 86100360 T AT86100360 T AT 86100360T AT E66469 T1 ATE66469 T1 AT E66469T1
Authority
AT
Austria
Prior art keywords
diagnosis
therapy
labeled protein
metal radionuclide
radionuclide labeled
Prior art date
Application number
AT86100360T
Other languages
English (en)
Inventor
Alan R Fritzberg
Original Assignee
Neorx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neorx Corp filed Critical Neorx Corp
Application granted granted Critical
Publication of ATE66469T1 publication Critical patent/ATE66469T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/04—Formation of amino groups in compounds containing carboxyl groups
    • C07C227/06—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid
    • C07C227/08—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid by reaction of ammonia or amines with acids containing functional groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
AT86100360T 1985-01-14 1986-01-13 Metall-radionuklid markiertes protein fuer diagnose und therapie. ATE66469T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69200085A 1985-01-14 1985-01-14
EP86100360A EP0188256B1 (de) 1985-01-14 1986-01-13 Metall-Radionuklid markiertes Protein für Diagnose und Therapie

Publications (1)

Publication Number Publication Date
ATE66469T1 true ATE66469T1 (de) 1991-09-15

Family

ID=24778874

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86100360T ATE66469T1 (de) 1985-01-14 1986-01-13 Metall-radionuklid markiertes protein fuer diagnose und therapie.

Country Status (5)

Country Link
EP (1) EP0188256B1 (de)
JP (2) JPH0662555B2 (de)
AT (1) ATE66469T1 (de)
CA (1) CA1336076C (de)
DE (1) DE3680924D1 (de)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5271927A (en) * 1986-02-13 1993-12-21 Celltech Limited Antibody conjugates with macrocyclic ligands
US4877868A (en) * 1986-03-12 1989-10-31 Neorx Corporation Radionuclide antibody coupling
US4965392A (en) * 1987-03-26 1990-10-23 Neorx Corporation Chelating compounds for metal-radionuclide labeled proteins
DE3889956T2 (de) * 1987-03-26 1994-12-22 Neorx Corp Metall-Radionuklid-markierte Proteine und Glykoproteine zur Diagnose und Therapie.
US5091514A (en) * 1987-03-26 1992-02-25 Neorx Corporation Metal-radionuclide-labeled proteins and glycoproteins for diagnosis and therapy
DE3710730A1 (de) * 1987-03-31 1988-10-20 Schering Ag Substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
US5177192A (en) * 1987-04-02 1993-01-05 Centocor, Incorporated Method for labeling antibodies with a metal ion
US5053493A (en) * 1987-04-02 1991-10-01 Centocor Cardiovascular Imaging Partners, L.P. Method for labeling antibodies with a metal ion
DE3850497T2 (de) * 1987-04-02 1995-02-23 Centocor Inc Methode zur markierung von antikörpern mit einem metallion.
EP0300431A3 (de) * 1987-07-22 1990-06-27 Neorx Corporation Methode zur Bindung von radionukliden Anschwefel enthaltende Chelate
US5021556A (en) * 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
IL87405A0 (en) * 1987-08-12 1989-01-31 Immunomedics Inc Radiolabeled agents and methods and kits for the production thereof
GB8719041D0 (en) * 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
US4933470A (en) * 1987-10-05 1990-06-12 Neorx Corporation Method of synthesis of vicinal diamines
US5648471A (en) * 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
IL89222A (en) * 1988-02-09 1995-03-30 Mallinckrodt Inc Preparation of metal-radionuclide-labelled proteins, certain novel compounds used therein and radiopharmaceutical compositions containing the labelled proteins
US5202451A (en) * 1988-02-17 1993-04-13 Neorx Corporation Anchimeric radiometal chelating compounds
US5075099A (en) * 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US4988496A (en) * 1988-05-31 1991-01-29 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5202109A (en) * 1988-06-10 1993-04-13 Neorx Corporation Conjugates for bone imaging and bone cancer therapy
US5089249A (en) * 1988-06-10 1992-02-18 Neorx Corporation Conjugates for bone imaging and bone cancer therapy
US5218128A (en) * 1988-06-15 1993-06-08 Centocor, Inc. Bifunctional coupling agents and radionuclide labeled compositions prepared therefrom
US4839467A (en) * 1988-06-15 1989-06-13 University Of Cincinnati Radioactive rhenium complexed to 2-hydroxy isobutyric acid
US5180816A (en) * 1988-08-24 1993-01-19 Centocor One vial method for labeling protein/linker conjugates with technetium-99M
US5066789A (en) * 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
DE68924783T2 (de) * 1988-09-30 1996-03-28 Neorx Corp Wässrige additivsysteme, verfahren und polymerteilchen.
US4925650A (en) * 1988-11-16 1990-05-15 Mallinckrodt, Inc. Technetium -99m complex for examining the renal function
ATE133165T1 (de) * 1989-02-10 1996-02-15 Celltech Therapeutics Ltd Aza-macrozyklen und verfahren zu deren herstellung
US5342936A (en) * 1989-02-10 1994-08-30 David Parker Tetra-aza macrocycles and processes for their preparation
US5053503A (en) * 1989-02-17 1991-10-01 Centocor Chelating agents
US5206370A (en) * 1989-02-24 1993-04-27 Johnson Matthey, Inc. Certain pyridyl hydrazines and hydrazides useful for protein labeling
US5162240A (en) * 1989-06-16 1992-11-10 Hitachi, Ltd. Method and apparatus of fabricating electric circuit pattern on thick and thin film hybrid multilayer wiring substrate
US5247077A (en) * 1989-06-23 1993-09-21 Celltech Limited Tri-aza macrocycles and processes for their preparation
US5443816A (en) * 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
DE3930674A1 (de) * 1989-09-11 1991-03-21 Diagnostikforschung Inst Bifunktionelle chelatbildner zur komplexierung von tc- und re-isotopen, verfahren zu ihrer herstellung und darstellung von konjugaten daraus sowie deren verwendung in diagnostik und therapie
US5162505A (en) * 1989-09-19 1992-11-10 Centocor Proteins modified with positively charged carriers and compositions prepared therefrom
US5112953A (en) * 1989-12-29 1992-05-12 Neorx Corporation Radiolabeled proteins for diagnostic or therapeutic use
US5185433A (en) * 1990-04-09 1993-02-09 Centocor, Inc. Cross-linking protein compositions having two or more identical binding sites
NZ237868A (en) * 1990-04-18 1994-04-27 Celltech Ltd Paramagnetic metal complexes of 1,4,7,10-tetracyclododecane derivatives and their use as nmr imaging agents
US5684135A (en) * 1990-04-18 1997-11-04 Celltech Therapeutics Limited Conjugate compounds containing aza-macro-cycles and processes for their preparation
US5080883A (en) * 1990-05-11 1992-01-14 Mallinckrodt, Inc. 99 mtcn3s-conjugated anti-bibrin monoclonal antibody as an in vivo diagnostic agent for imaging
US5382654A (en) * 1992-02-05 1995-01-17 Mallinckrodt Medical, Inc. Radiolabelled peptide compounds
AU8730691A (en) * 1990-09-28 1992-04-28 Neorx Corporation Polymeric carriers for release of covalently linked agents
US5849261A (en) * 1991-02-08 1998-12-15 Diatide, Inc. Radiolabeled vasoactive intestinal peptides for diagnosis and therapy
US5443815A (en) * 1991-11-27 1995-08-22 Diatech, Inc. Technetium-99m labeled peptides for imaging
US6019958A (en) * 1991-02-08 2000-02-01 Diatide, Inc. Technetium-99m labeled peptides for imaging inflammation
US6107459A (en) * 1991-02-08 2000-08-22 Diatide, Inc. Technetium-99m labeled peptides for diagnostic imaging
US5645815A (en) * 1991-02-08 1997-07-08 Diatide, Inc. Radiolabled compounds for thrombus imaging
CA2101942C (en) * 1991-02-08 2001-01-30 Richard T. Dean Technetium-99m labeled polypeptides for imaging
US5561220A (en) * 1991-02-08 1996-10-01 Diatech, Inc. Technetium-99m labeled peptides for imaging inflammation
US5965107A (en) * 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
US5736122A (en) * 1991-02-08 1998-04-07 Diatide, Inc. Technetium-99m labeled peptides for thrombus imaging
US5997844A (en) * 1991-02-08 1999-12-07 Diatide, Inc. Technetium-99m labeled peptides for imaging
GB9113487D0 (en) * 1991-06-21 1991-08-07 Amersham Int Plc Agents for hypoxic cells
US5225180A (en) * 1991-09-10 1993-07-06 Diatech, Inc. Technetium-99m labeled somatostatin-derived peptides for imaging
US5783170A (en) * 1991-11-27 1998-07-21 Diatide, Inc. Peptide-metal chelate conjugates
US5643549A (en) * 1992-02-20 1997-07-01 Rhomed Incorporated Leukostimulatory agent for in vivo leukocyte tagging
US5326856A (en) * 1992-04-09 1994-07-05 Cytogen Corporation Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
US5508020A (en) 1992-06-05 1996-04-16 Diatech, Inc. Technetium-99M labeled peptides for imaging
US5968476A (en) * 1992-05-21 1999-10-19 Diatide, Inc. Technetium-99m labeled peptides for thrombus imaging
DE4301871A1 (de) * 1993-01-13 1994-07-14 Diagnostikforschung Inst Neue Mittel zur Diagnose von Gefäßerkrankungen
US5879657A (en) * 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
DE4311023C2 (de) * 1993-03-31 1996-05-02 Diagnostikforschung Inst Bifunktionelle chalkogenatom-unterbrochene Chelatbildner von Typ XN¶1¶S¶1¶O¶1¶ für radioaktive Isotope, deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel
DE4310999C2 (de) * 1993-03-31 1996-07-18 Diagnostikforschung Inst Bifunktionelle chalkogenatom-unterbrochene Chelatbildner vom Typ XN¶1¶S¶1¶X' für radioaktive Isotope und deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel
AU6493894A (en) * 1993-03-31 1994-10-24 Mallinckrodt Medical, Inc. Radiopharmaceutical formulations having non-stannous reductants
DE4311022C2 (de) * 1993-03-31 1996-07-11 Diagnostikforschung Inst Bifunktionelle chalkogenatom-unterbrochene Chelatbildner vom Typ S¶3¶N¶2¶ für radioaktive Isotope und deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel
JPH08510258A (ja) * 1993-05-14 1996-10-29 マリンクロット・メディカル・インコーポレイテッド ペプチド内へ導入するための配位子前駆体
US5449761A (en) * 1993-09-28 1995-09-12 Cytogen Corporation Metal-binding targeted polypeptide constructs
WO1995034315A1 (en) * 1994-06-16 1995-12-21 Neorx Corporation Radiolabeled annexin-galactose conjugates
US5942210A (en) * 1994-11-15 1999-08-24 Cytogen Corporation Methods for lyoprotecting a macromolecule using tricine
DE19505960A1 (de) * 1995-02-21 1996-08-22 Deutsches Krebsforsch Konjugat zur individuellen Dosierung von Arzneimitteln
CA2245835A1 (en) 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
DE19536780A1 (de) * 1995-09-21 1997-03-27 Diagnostikforschung Inst Bifunktionelle sulfidhaltige Sulfonamid-Chelatbildner vom Typ XSNY für radioaktive Isotope
EP0869820B1 (de) * 1995-12-28 2005-03-09 The General Hospital Corporation Verbindungen, verfahren und kits zur bildgebung des kardiovaskulären systems und von thromben
US6187286B1 (en) * 1996-12-27 2001-02-13 The General Hospital Corporation Tumor imaging agents, methods and kits
US6960457B1 (en) 1997-09-04 2005-11-01 Stanford University Reversible immobilization of arginine-tagged moieties on a silicate surface
AU2002226876A1 (en) 2000-10-06 2002-04-15 Quantum Dot Corporation Cells having a spectral signature, and methods of preparation and use thereof
US20050059031A1 (en) 2000-10-06 2005-03-17 Quantum Dot Corporation Method for enhancing transport of semiconductor nanocrystals across biological membranes
US7378280B2 (en) 2000-11-16 2008-05-27 California Institute Of Technology Apparatus and methods for conducting assays and high throughput screening
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
JP4342934B2 (ja) 2001-06-11 2009-10-14 キセノポート インコーポレーティッド Ｐｅｐｔ−２輸送体を介した薬剤の投与
CA2467587A1 (en) 2001-11-30 2003-06-12 Fluidigm Corporation Microfluidic device and methods of using same
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
NZ538284A (en) 2002-07-18 2008-04-30 Helix Biopharma Corp Use of urease and targeting molecule for inhibiting cancer cell growth
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
GB0416062D0 (en) * 2004-07-19 2004-08-18 Amersham Plc Improved N4 chelator conjugates
GB2426521A (en) 2004-02-02 2006-11-29 Ambrx Inc Modified human four helical bundle polypeptides and their uses
CN102532321B (zh) 2004-06-18 2018-10-12 Ambrx公司 新颖抗原结合多肽和其用途
CA2569381A1 (en) 2004-07-21 2006-08-31 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US7939496B2 (en) 2004-12-22 2011-05-10 Ambrx, Inc. Modified human growth horomone polypeptides and their uses
NZ555308A (en) 2004-12-22 2010-10-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
WO2007059312A2 (en) 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
EP2615108B1 (de) 2006-09-08 2016-10-26 Ambrx, Inc. Modifiziertes humanes Plasmapolypeptid oder Fc-Gerüste und deren Verwendungen
AU2008222678B2 (en) 2007-03-07 2013-01-17 The General Hospital Corporation Compositions and methods for the prevention and treatment of autoimmune conditions
KR20140012199A (ko) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
EP2348052A3 (de) 2007-09-17 2011-10-26 The Regents of The University of California Auf Prostatazellen in situ abzielende internalisierende humane monoklonale Antikörper
CA2699944C (en) 2007-09-21 2017-11-14 The Regents Of The University Of California Targeted interferon demonstrates potent apoptotic and anti-tumor activities
DK2217265T3 (en) 2007-11-20 2017-07-03 Ambrx Inc Modified insulin polypeptides and their use
CN103694337B (zh) 2008-02-08 2016-03-02 Ambrx公司 经修饰瘦素多肽和其用途
WO2010011735A2 (en) 2008-07-23 2010-01-28 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
AU2009296267B2 (en) 2008-09-26 2013-10-31 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
JP5694171B2 (ja) 2008-09-26 2015-04-01 アンブルックス, インコーポレイテッドAmbrx, Inc. 修飾されている動物のエリスロポエチンポリペプチドおよびそれらの使用
AU2010210600B2 (en) 2009-02-06 2016-07-14 C3 Jian, Inc. Calcium-binding agents induce hair growth and/or nail growth
EA201290542A1 (ru) 2009-12-21 2013-07-30 Амбркс, Инк. Модифицированные свиные соматотропиновые полипептиды и их применение
JP2013515080A (ja) 2009-12-21 2013-05-02 アンブルックス，インコーポレイテッド 修飾されているウシのソマトトロピンポリペプチドおよびそれらの使用
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
ES2972902T3 (es) 2010-08-17 2024-06-17 Ambrx Inc Polipéptidos de relaxina modificados y sus usos
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
US9090691B2 (en) 2010-09-15 2015-07-28 Applied Molecular Transport Llc Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
US20120093934A1 (en) 2010-09-29 2012-04-19 Uti Limited Partnership Methods for treating autoimmune disease using biocompatible bioabsorbable nanospheres
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
WO2012125582A1 (en) 2011-03-11 2012-09-20 Board Of Regents Of The University Of Nebraska Biomarker for coronary artery disease
WO2012138941A1 (en) 2011-04-05 2012-10-11 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
PE20140784A1 (es) 2011-05-27 2014-07-03 Ambrx Inc Composiciones que contienen, metodos que involucran, y usos de derivados de dolastatina unidos a aminoacidos no naturales
MX345538B (es) 2011-05-27 2017-02-03 Ambrx Inc Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales.
AU2013215796B2 (en) * 2012-02-03 2016-09-15 Lg Chem, Ltd. Method for preparing compound by novel Michael addition reaction using water or various acids as additive
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
MX363116B (es) 2012-06-07 2019-03-11 Ambrx Inc Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata.
SG11201408347UA (en) 2012-06-14 2015-01-29 Ambrx Inc Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
MX359449B (es) 2012-06-19 2018-09-28 Ambrx Inc Conjugados de anticuerpo fármaco anti-cd70.
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
US9789164B2 (en) 2013-03-15 2017-10-17 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
WO2015066543A1 (en) 2013-11-01 2015-05-07 Board Of Regents, The University Of Texas System Targeting her2 and her3 with bispecific antibodies in cancerous cells
EP3065771B1 (de) 2013-11-04 2019-03-20 UTI Limited Partnership Verfahren und zusammensetzungen für retard-immuntherapie
ES2900328T3 (es) 2014-05-07 2022-03-16 Applied Molecular Transport Inc Moléculas de fusión derivadas de toxina Cholix para la administración oral de carga biológicamente activa
MX2017004947A (es) 2014-10-24 2017-06-29 Bristol Myers Squibb Co Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
JP6920211B2 (ja) 2015-05-06 2021-08-18 ユーティーアイ リミテッド パートナーシップ 持続療法用のナノ粒子組成物
US10193422B2 (en) 2015-05-13 2019-01-29 Makita Corporation Power tool
AU2016349786C1 (en) 2015-11-03 2024-11-07 Ambrx, Inc. Anti-CD3-folate conjugates and their uses
SI3383920T1 (sl) 2015-11-30 2024-06-28 The Regents Of The University Of California Dostava tumorsko specifičnega koristnega tovora in imunska aktivacija z uporabo humanega protitelesa, ki cilja visoko specifičen površinski antigen tumorskih celic
WO2017180789A2 (en) 2016-04-12 2017-10-19 Blaze Bioscience, Inc. Methods of treatment using chlorotoxin conjugates
US12048732B2 (en) 2016-04-15 2024-07-30 Blaze Bioscience, Inc. Methods of treating breast cancer
WO2018089829A1 (en) 2016-11-10 2018-05-17 Fortis Therapeutics, Inc. Cd46-specific effector cells and uses thereof
CA3043277A1 (en) 2016-11-11 2018-05-17 The Regents Of The University Of California Anti-cd46 antibodies and methods of use
US20180163270A1 (en) 2016-12-12 2018-06-14 Cepheid Integrated immuno-pcr and nucleic acid analysis in an automated reaction cartridge
CA3049212A1 (en) 2017-01-05 2018-07-12 The Regents Of The University Of California Pac1 receptor agonists (maxcaps) and uses thereof
ES2963839T3 (es) 2017-02-08 2024-04-02 Bristol Myers Squibb Co Polipéptidos de relaxina modificados que comprenden un potenciador farmacocinético y usos de los mismos
EP4316586A3 (de) 2018-03-08 2024-05-08 Applied Molecular Transport Inc. Toxinabgeleitete freisetzungskonstrukte zur oralen freisetzung
SMT202400364T1 (it) 2018-03-29 2024-11-15 Ambrx Inc Coniugati farmaco-anticorpo anti-antigene prostatico-specifico di membrana (psma) umanizzato
CN111417655A (zh) 2018-08-28 2020-07-14 润俊(中国)有限公司 抗cd3抗体叶酸生物偶联物及其用途
US12049485B2 (en) 2018-09-11 2024-07-30 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
WO2020082057A1 (en) 2018-10-19 2020-04-23 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
PL3650037T3 (pl) 2018-11-07 2022-06-06 Applied Molecular Transport Inc. Konstrukty dostarczające do transcytozy i powiązane z nimi sposoby
WO2020168017A1 (en) 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
CN114599665A (zh) 2019-08-16 2022-06-07 应用分子转运公司 组合物、制剂及白细胞介素产生和纯化
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
CA3174114A1 (en) 2020-03-11 2021-09-16 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
BR112023002346A2 (pt) 2020-08-07 2023-05-02 Fortis Therapeutics Inc Imunoconjugados direcionados a cd46 e métodos de uso dos mesmos
JP2023538071A (ja) 2020-08-20 2023-09-06 アンブルックス，インコーポレイテッド 抗体－ｔｌｒアゴニストコンジュゲート、その方法及び使用
KR20240004342A (ko) 2021-04-03 2024-01-11 암브룩스, 인코포레이티드 항-her2 항체-약물 접합체 및 이의 용도
WO2024077277A1 (en) 2022-10-07 2024-04-11 Ambrx, Inc. Drug linkers and antibody conjugates thereof
WO2024155627A1 (en) 2023-01-16 2024-07-25 Ambrx, Inc. Anti-cd70 antibody-drug conjugates
WO2024178310A1 (en) 2023-02-23 2024-08-29 Ambrx, Inc. Trop2-directed antibody-drug conjugates and uses thereof
WO2025041055A1 (en) 2023-08-22 2025-02-27 Ambrx, Inc. Anti-psma adc conjugate compositions and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673562A (en) * 1983-08-19 1987-06-16 The Children's Medical Center Corporation Bisamide bisthiol compounds useful for making technetium radiodiagnostic renal agents

Also Published As

Publication number Publication date
JPS61225163A (ja) 1986-10-06
JPH06122691A (ja) 1994-05-06
JPH07103159B2 (ja) 1995-11-08
CA1336076C (en) 1995-06-27
EP0188256A3 (en) 1987-05-13
EP0188256A2 (de) 1986-07-23
DE3680924D1 (de) 1991-09-26
JPH0662555B2 (ja) 1994-08-17
EP0188256B1 (de) 1991-08-21

Similar Documents

Publication Publication Date Title
ATE66469T1 (de) Metall-radionuklid markiertes protein fuer diagnose und therapie.
ATE106898T1 (de) Metall-radionuklid-markierte proteine und glykoproteine zur diagnose und therapie.
DE68912302D1 (de) Härtendes material für medizinischen und dentalen gebrauch.
IT8619338A0 (it) Peptide sintetico ad attivita'interleukina 1 umana.
DE3577185D1 (de) Paramagnetische kontrastmittel fuer die anwendung in "in vivo" nmr-diagnostischen methoden und die herstellung davon.
AU6198086A (en) Agents for use in tumour diagnosis, imaging, localization or treatment
FI872756A0 (fi) Med laserstraolning fungerande terapeutisk anordning.
DE3672816D1 (de) Kontrastmittel fuer nmr-abbildung.
AT386331B (de) Handstueck, insbesondere fuer zahnaerztliche zwecke
DE69131881D1 (de) 99mTc MARKIERTE LIPOSOMEN
DE3573661D1 (en) Diagnostic agent for heart disease and use thereof
DK0478631T3 (da) Målsøgende midler
IT8419730A0 (it) Procedimento per la trasformazione quantitativa di teicoplanina a2fattore 1 in teicoplanina a2fattore 3.
DE3886517D1 (de) Menschlicher Prourokinase ähnliches Polypeptid.
IT8547856A0 (it) Espressione in e. coli polipeptidi ibridi contenenti la sequenza del fattore di rilascio dell'ormone del la crescita
EP0280135A3 (en) Protein c-inhibitor (pci) as a pharmaceutical and diagnostic agent, process for the preparation of such a pharmaceutical or diagnostic agent and a composition containing pci
IT1222701B (it) Composizione ad uso topico avente attivita' tricogena,antiforfora ed antiseborroica
DE69000791D1 (de) Therapeutische mittel fuer metabolische knochenkrankheiten.
EP0200214A3 (en) Treatment of parasitic diseases
SU1593579A3 (ru) Диaгhoctичeckoe cpeдctbo для oпpeдeлehия бpушиta b пoчeчhыx kamhяx
ATE47028T1 (de) Dentale verankerung fuer herausnehmbare teilprothese.
ATE98990T1 (de) Menschlicher prourokinase aehnliches polypeptid.
ATE52032T1 (de) Paramagnetische kontrastmittel fuer die anwendung in ''in vivo'' nmr-diagnostischen methoden und die herstellung davon.
IT1222074B (it) Composizione ad attivita' antiforfora
IE850292L (en) Ceramic-metallic dental reconstruction

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee